Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Diagnostic & Testing Equipment
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CPHD
- CUSIP: 15670R10
- Web: www.cepheid.com
Average Prices:- 50 Day Moving Avg: $52.75
- 200 Day Moving Avg: $38.36
- 52 Week Range: $25.09 - $53.91
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 53.48
- P/E Growth: 0.00
Profitability:- Net Margins: -6.88%
- Return on Equity: -11.54%
- Return on Assets: -5.18%
Debt:- Debt-to-Equity Ratio: 0.76%
- Current Ratio: 4.30%
- Quick Ratio: 3.24%
Misc:- Average Volume: 2.11 million shs.
- Beta: 0.67
Frequently Asked Questions for Cepheid (NASDAQ:CPHD)
What is Cepheid's stock symbol?
Cepheid trades on the NASDAQ under the ticker symbol "CPHD."
How were Cepheid's earnings last quarter?
Cepheid (NASDAQ:CPHD) released its earnings results on Thursday, July, 28th. The company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.19. The company had revenue of $146 million for the quarter, compared to analysts' expectations of $145.82 million. Cepheid had a negative net margin of 6.88% and a negative return on equity of 11.54%. The firm's revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.06) EPS. View Cepheid's Earnings History.
Who are some of Cepheid's key competitors?
Some companies that are related to Cepheid include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), VCA (WOOF), Valeant Pharmaceuticals Intl (VRX), NMC Health PLC (NMC), ConvaTec Group PLC (CTEC), Health Net (HNT), Catalent (CTLT), Patheon NV (PTHN), Mediclinic International PLC (MDC), Puma Biotechnology (PBYI), Cotiviti Holdings (COTV) and WuXi PharmaTech (Cayman) (WX).
How do I buy Cepheid stock?
Shares of Cepheid can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cepheid's stock price today?
One share of Cepheid stock can currently be purchased for approximately $52.95.
MarketBeat Community Rating for Cepheid (NASDAQ CPHD)MarketBeat's community ratings are surveys of what our community members think about Cepheid and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cepheid (NASDAQ:CPHD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating |
| Consensus Rating: | Hold (Score: 2.00) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Cepheid (NASDAQ:CPHD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 11/22/2016 | Canaccord Genuity | Reiterated Rating | Hold | | N/A |  |
| 9/12/2016 | Robert W. Baird | Downgrade | Outperform -> Neutral | $53.00 | N/A | |
| 9/8/2016 | Citigroup Inc. | Downgrade | Buy -> Neutral | $44.00 -> $53.00 | N/A | |
| 9/7/2016 | Barclays PLC | Boost Price Target | Equal Weight | $36.00 -> $52.00 | N/A | |
| 9/7/2016 | BTIG Research | Downgrade | Buy -> Neutral | | N/A | |
| 9/7/2016 | Cowen and Company | Downgrade | Outperform -> Market Perform | | N/A | |
| 9/6/2016 | Craig Hallum | Downgrade | Buy -> Hold | | N/A | |
| 9/6/2016 | Piper Jaffray Companies | Downgrade | Overweight -> Neutral | | N/A | |
| 9/6/2016 | Needham & Company LLC | Downgrade | Buy -> Hold | | N/A | |
| 8/17/2016 | Jefferies Group LLC | Boost Price Target | Hold | $28.00 -> $34.00 | N/A | |
| 7/29/2016 | J P Morgan Chase & Co | Boost Price Target | Neutral | $32.00 -> $35.00 | N/A | |
| 6/15/2016 | Morgan Stanley | Initiated Coverage | Equal Weight | $30.00 | N/A | |
| 4/1/2016 | Atlantic Securities | Upgrade | Neutral -> Overweight | | N/A | |
| 3/28/2016 | Wedbush | Lower Price Target | Outperform | $58.00 -> $55.00 | N/A | |
| 2/3/2016 | Stifel Nicolaus | Lower Price Target | Buy | $42.00 -> $38.00 | N/A | |
| 2/3/2016 | Leerink Swann | Reiterated Rating | Market Perform | $39.00 -> $33.00 | N/A | |
| 1/6/2016 | Avondale Partners | Initiated Coverage | Outperform | $46.00 | N/A | |
| 12/2/2015 | Wells Fargo & Company | Downgrade | Outperform -> Market Perform | | N/A | |
| 10/21/2015 | Evercore ISI | Upgrade | Sell -> Hold | $44.50 -> $32.50 | N/A | |
| 10/21/2015 | Mizuho | Lower Price Target | Buy | $60.00 -> $42.00 | N/A | |
| 10/14/2015 | Goldman Sachs Group, Inc. (The) | Lower Price Target | | $53.00 -> $30.00 | N/A | |
| 10/14/2015 | Raymond James Financial, Inc. | Downgrade | Outperform -> Market Perform | | N/A | |
(Data available from 9/24/2015 forward)
Earnings History for Cepheid (NASDAQ:CPHD)Earnings History by Quarter for Cepheid (NASDAQ CPHD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/28/2016 | Q216 | ($0.14) | $0.05 | $145.82 million | $146.00 million | View | Listen | |
| 4/28/2016 | Q116 | $0.01 | $0.08 | $140.35 million | $144.80 million | View | N/A | |
| 2/2/2016 | Q415 | ($0.20) | ($0.14) | $146.95 million | $147.00 million | View | N/A | |
| 10/20/2015 | Q3 | ($0.31) | ($0.13) | $126.81 million | $126.50 million | View | Listen | |
| 7/23/2015 | Q215 | ($0.21) | ($0.06) | $130.70 million | $132.50 million | View | Listen | |
| 4/23/2015 | Q115 | ($0.17) | $0.06 | $125.50 million | $132.60 million | View | N/A | |
| 1/29/2015 | Q414 | ($0.13) | $0.11 | $125.34 million | $131.50 million | View | N/A | |
| 10/16/2014 | Q314 | ($0.16) | ($0.10) | $110.10 million | $115.20 million | View | Listen | |
| 7/17/2014 | Q214 | ($0.13) | ($0.10) | $115.47 million | $116.50 million | View | N/A | |
| 4/17/2014 | Q114 | ($0.19) | ($0.13) | $104.90 million | $106.90 million | View | N/A | |
| 1/30/2014 | Q413 | ($0.10) | ($0.07) | $102.17 million | $113.30 million | View | N/A | |
| 7/18/2013 | Q2 2013 | $0.04 | $0.02 | $92.57 million | $96.00 million | View | N/A | |
| 4/18/2013 | Q1 2013 | $0.10 | $0.11 | $89.12 million | $91.90 million | View | N/A | |
| 1/24/2013 | Q4 2012 | $0.11 | $0.20 | $92.87 million | $92.40 million | View | N/A | |
| 10/18/2012 | | ($0.07) | ($0.32) | | | View | N/A | |
| 7/19/2012 | | $0.11 | $0.11 | | | View | N/A | |
| 4/19/2012 | | ($0.01) | ($0.08) | | | View | N/A | |
| 1/26/2012 | | ($0.02) | ($0.03) | | | View | N/A | |
| 10/20/2011 | | $0.02 | $0.03 | | | View | N/A | |
| 7/21/2011 | | ($0.01) | $0.03 | | | View | N/A | |
| 4/20/2011 | | ($0.01) | $0.01 | | | View | N/A | |
| 1/27/2011 | | ($0.02) | $0.02 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cepheid (NASDAQ:CPHD)Current Year EPS Consensus Estimate: $0.33 EPS
Next Year EPS Consensus Estimate: $0.99 EPS
Dividend History for Cepheid (NASDAQ:CPHD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cepheid (NASDAQ:CPHD)Insider Ownership Percentage: 4.16%
Institutional Ownership Percentage: 95.75%
Insider Trades by Quarter for Cepheid (NASDAQ:CPHD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/17/2016 | Scott A Campbell | VP | Sell | 287 | $36.16 | $10,377.92 | |
| 8/4/2016 | Scott A Campbell | VP | Sell | 746 | $36.71 | $27,385.66 | |
| 5/3/2016 | Scott A Campbell | VP | Sell | 2,058 | $27.90 | $57,418.20 | |
| 5/2/2016 | Peter V Farrell | EVP | Sell | 390 | $28.90 | $11,271.00 | |
| 4/28/2016 | Peter V Farrell | EVP | Sell | 390 | $36.30 | $14,157.00 | |
| 4/25/2016 | John L Bishop | CEO | Sell | 110,000 | $35.50 | $3,905,000.00 | |
| 3/10/2016 | Peter V Farrell | EVP | Sell | 393 | $33.01 | $12,972.93 | |
| 2/8/2016 | Warren C. Kocmond, Jr. | COO | Sell | 292 | $28.53 | $8,330.76 | |
| 2/1/2016 | Warren C. Kocmond, Jr. | COO | Sell | 351 | $28.44 | $9,982.44 | |
| 1/22/2016 | Warren C. Kocmond, Jr. | COO | Sell | 157 | $33.16 | $5,206.12 | |
| 12/10/2015 | Peter V. Farrell | EVP | Sell | 394 | $31.67 | $12,477.98 | |
| 11/20/2015 | Robert J Easton | Director | Sell | 3,206 | $36.02 | $115,480.12 | |
| 11/17/2015 | Robert J Easton | Director | Sell | 2,724 | $34.84 | $94,904.16 | |
| 11/12/2015 | Robert J Easton | Director | Sell | 2,556 | $35.01 | $89,485.56 | |
| 10/30/2015 | Peter V. Farrell | EVP | Sell | 1,560 | $33.89 | $52,868.40 | |
| 8/27/2015 | Peter V. Farrell | EVP | Sell | 1,577 | $48.67 | $76,752.59 | |
| 8/25/2015 | Cristina Kepner | Director | Buy | 10,000 | $47.78 | $477,800.00 | |
| 6/26/2015 | Warren C Kocmond Jr | COO | Sell | 9,375 | $61.52 | $576,750.00 | |
| 4/29/2015 | Thomas L Gutshall | Director | Sell | 1,800 | $56.62 | $101,916.00 | |
| 4/21/2015 | Joseph H Smith | EVP | Sell | 91,866 | $54.51 | $5,007,615.66 | |
| 4/20/2015 | John L Bishop | CEO | Sell | 100,000 | $55.20 | $5,520,000.00 | |
| 2/25/2015 | Hollings Renton | Director | Sell | 9,375 | $57.76 | $541,500.00 | |
| 2/13/2015 | Dean O Morton | Director | Sell | 12,500 | $58.51 | $731,375.00 | |
| 2/3/2015 | Thomas D Brown | Director | Sell | 12,500 | $56.29 | $703,625.00 | |
| 1/30/2015 | Andrew Miller | CFO | Sell | 6,677 | $57.64 | $384,862.28 | |
| 1/12/2015 | Andrew Miller | CFO | Sell | 11,719 | $56.65 | $663,881.35 | |
| 1/12/2015 | David H Persing | EVP | Sell | 5,000 | $56.90 | $284,500.00 | |
| 1/12/2015 | Warren C Kocmond Jr | COO | Sell | 4,688 | $57.00 | $267,216.00 | |
| 1/5/2015 | Andrew Miller | CFO | Sell | 2,250 | $54.95 | $123,637.50 | |
| 1/5/2015 | Kerry Flom | EVP | Sell | 8,694 | $54.21 | $471,301.74 | |
| 11/19/2014 | Dean O Morton | Director | Sell | 11,849 | $52.96 | $627,523.04 | |
| 11/7/2014 | Hollings Renton | Director | Sell | 9,375 | $51.07 | $478,781.25 | |
| 10/31/2014 | Andrew Miller | CFO | Sell | 12,167 | $53.84 | $655,071.28 | |
| 10/31/2014 | David H Persing | EVP | Sell | 20,000 | $53.34 | $1,066,800.00 | |
| 10/31/2014 | Dean O Morton | Director | Sell | 7,500 | $52.64 | $394,800.00 | |
| 10/29/2014 | Kerry Flom | EVP | Sell | 7,077 | $51.36 | $363,474.72 | |
| 10/29/2014 | Thomas L Gutshall | Director | Sell | 12,500 | $51.63 | $645,375.00 | |
| 10/28/2014 | David H Persing | EVP | Sell | 15,000 | $51.51 | $772,650.00 | |
| 10/3/2014 | Kerry Flom | EVP | Sell | 1,271 | $44.52 | $56,584.92 | |
| 8/7/2014 | Warren C Kocmond Jr | EVP | Sell | 324 | $38.69 | $12,535.56 | |
| 7/14/2014 | Kerry Flom | EVP | Sell | 2,812 | $49.72 | $139,812.64 | |
| 7/3/2014 | Kerry Flom | EVP | Sell | 1,282 | $48.97 | $62,779.54 | |
| 5/29/2014 | Kerry Flom | EVP | Sell | 4,265 | $45.49 | $194,014.85 | |
| 5/22/2014 | Warren C Kocmond Jr | EVP | Sell | 1,300 | $42.38 | $55,094.00 | |
| 4/29/2014 | Kerry Flom | EVP | Sell | 2,660 | $42.38 | $112,730.80 | |
| 4/25/2014 | John Bishop | CEO | Sell | 107,651 | $43.93 | $4,729,108.43 | |
| 4/22/2014 | John Bishop | CEO | Sell | 42,349 | $46.11 | $1,952,712.39 | |
| 4/22/2014 | Robert Easton | Director | Sell | 12,500 | $45.59 | $569,875.00 | |
| 4/3/2014 | Kerry Flom | EVP | Sell | 1,621 | $51.55 | $83,562.55 | |
| 4/1/2014 | Andrew Miller | CFO | Sell | 4,688 | $52.78 | $247,432.64 | |
| 3/13/2014 | Andrew Miller | CFO | Sell | 17,265 | $55.55 | $959,070.75 | |
| 1/31/2014 | Andrew Miller | CFO | Sell | 63,375 | $53.10 | $3,365,212.50 | |
| 1/31/2014 | John Bishop | CEO | Sell | 150,000 | $50.67 | $7,600,500.00 | |
| 1/31/2014 | Joseph Smith | EVP | Sell | 50,000 | $51.15 | $2,557,500.00 | |
| 1/3/2014 | Kerry Flom | EVP | Sell | 6,357 | $45.66 | $290,260.62 | |
| 1/2/2014 | Andrew Miller | CFO | Sell | 2,437 | $45.92 | $111,907.04 | |
| 12/23/2013 | Kerry Flom | EVP | Sell | 10,000 | $46.51 | $465,100.00 | |
| 10/30/2013 | David H Persing | VP | Sell | 5,000 | $41.35 | $206,750.00 | |
| 10/29/2013 | Kerry Flom | EVP | Sell | 2,660 | $40.50 | $107,730.00 | |
| 10/24/2013 | Thomas L Gutshall | Director | Sell | 3,000 | $40.07 | $120,210.00 | |
| 10/18/2013 | David H Persing | VP | Sell | 20,000 | $40.59 | $811,800.00 | |
| 9/24/2013 | Thomas Gutshall | Director | Sell | 3,000 | $38.97 | $116,910.00 | |
| 9/18/2013 | David Persing | VP | Sell | 5,000 | $39.34 | $196,700.00 | |
| 9/16/2013 | David Persing | VP | Sell | 5,000 | $38.95 | $194,750.00 | |
| 9/6/2013 | David H Persing | VP | Sell | 20,000 | $37.99 | $759,800.00 | |
| 8/30/2013 | David Persing | VP | Sell | 5,129 | $36.62 | $187,823.98 | |
| 8/26/2013 | Thomas Gutshall | Director | Sell | 3,000 | $36.38 | $109,140.00 | |
| 8/21/2013 | Robert Easton | Director | Sell | 7,500 | $35.01 | $262,575.00 | |
| 7/24/2013 | Thomas L Gutshall | Director | Sell | 3,000 | $34.18 | $102,540.00 | |
| 6/24/2013 | Thomas L Gutshall | Director | Sell | 3,000 | $32.91 | $98,730.00 | |
| 5/28/2013 | Andrew Miller | CFO | Sell | 22,468 | $38.51 | $865,242.68 | |
| 5/24/2013 | Thomas L Gutshall | Director | Sell | 3,000 | $37.90 | $113,700.00 | |
| 5/13/2013 | Kerry Flom | EVP | Sell | 6,832 | $39.76 | $271,640.32 | |
| 3/25/2013 | Thomas L Gutshall | Director | Sell | 3,000 | $38.28 | $114,840.00 | |
| 2/4/2013 | Joseph H Smith | EVP | Sell | 38,400 | $36.20 | $1,390,080.00 | |
| 12/24/2012 | Thomas L Gutshall | Director | Sell | 3,000 | $33.06 | $99,180.00 | |
| 11/26/2012 | Thomas L Gutshall | Director | Sell | 7,778 | $31.94 | $248,429.32 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cepheid (NASDAQ:CPHD)
Latest Headlines for Cepheid (NASDAQ:CPHD)
| Source: |
|
| Date | Headline |
|---|
 | Head to Head Contrast: Cepheid (CPHD) vs. Varex Imaging (VREX)
www.americanbankingnews.com - September 9 at 4:06 AM |
| Contrasting Cepheid (CPHD) and HTG Molecular Diagnostics (HTGM)
www.americanbankingnews.com - August 5 at 7:06 AM |
| Financial Review: Sequenom (SQNM) & Cepheid (CPHD)
www.americanbankingnews.com - August 1 at 8:30 PM |
| Contrasting Cepheid (NASDAQ:CPHD) and Myriad Genetics (MYGN)
www.americanbankingnews.com - July 30 at 7:27 AM |
| Comparing Myriad Genetics (MYGN) & Cepheid (NASDAQ:CPHD)
www.americanbankingnews.com - July 29 at 10:11 AM |
| Reviewing Cepheid (CPHD) & Vascular Solutions (VASC)
www.americanbankingnews.com - July 28 at 7:14 AM |
| Head-To-Head Comparison: Myriad Genetics (MYGN) vs. Cepheid (CPHD)
www.americanbankingnews.com - July 22 at 7:36 AM |
| Head to Head Survey: Cepheid (NASDAQ:CPHD) versus Myriad Genetics (MYGN)
www.americanbankingnews.com - July 21 at 8:04 AM |
| Analyzing Cepheid (CPHD) and Alphatec Holdings (ATEC)
www.americanbankingnews.com - July 20 at 9:42 AM |
| Comparing Myriad Genetics (MYGN) & Cepheid (CPHD)
www.americanbankingnews.com - July 14 at 8:36 AM |
| Head-To-Head Comparison: Alphatec Holdings (ATEC) vs. Cepheid (NASDAQ:CPHD)
www.americanbankingnews.com - July 12 at 8:16 AM |
| Cepheid (CPHD) Earning Somewhat Positive News Coverage, Report Shows
www.americanbankingnews.com - April 27 at 10:22 PM |
 | These drug and medical device companies made the most payments to L.A. hospitals
www.bizjournals.com - March 3 at 9:29 PM |
 | Mario Gabelli Comments on Cepheid
finance.yahoo.com - January 31 at 4:58 PM |
 | Integrated Investment Consultants, LLC Buys Vanguard FTSE Emerging Markets, Mylan NV, Omega ...
www.nasdaq.com - January 19 at 10:48 PM |
 | Danaher initiates 2017 outlook
seekingalpha.com - December 15 at 4:53 PM |
| CEPHEID Financials
finance.yahoo.com - November 15 at 4:40 PM |
| CEPHEID Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or
biz.yahoo.com - November 7 at 11:02 PM |
 | Danaher (DHR) Announces Completion of Cepheid (CPHD) Acquisition - StreetInsider.com
www.streetinsider.com - November 7 at 7:55 AM |
| CEPHEID Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 3 at 9:56 PM |
| CEPHEID Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - October 28 at 9:11 PM |
| IWO, MSCC, AZPN, CPHD: Large Outflows Detected at ETF
www.nasdaq.com - October 25 at 9:37 PM |
| Cepheid Says Receives Regulatory Clearances In Proposed Acquisition By Danaher
www.nasdaq.com - October 24 at 4:16 PM |
| Cepheid (CPHD) Announces Final Regulatory Hurdles Cleared to Close Danaher (DHR) Merger
www.streetinsider.com - October 24 at 4:16 PM |
| Cepheid (CPHD) Announces Final Regulatory Hurdles Cleared to Close Danaher (DHR) Merger - StreetInsider.com
www.streetinsider.com - October 24 at 9:34 AM |
| CEPHEID Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - October 24 at 9:33 AM |
| What's in Store for Cepheid (CPHD) this Earnings Season?
finance.yahoo.com - October 17 at 4:22 PM |
| iShares Russell 2000 Growth ETF Experiences Big Outflow
www.nasdaq.com - October 14 at 4:15 PM |
| Exactech Enters Foot & Ankle Space with Vantage System
finance.yahoo.com - October 14 at 4:15 PM |
Cepheid (CPHD) Chart for Sunday, September, 24, 2017
